Printer Friendly

HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES

 HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES
 KANSAS CITY/SOMERVILLE, N.J., July 30 /PRNewswire/ -- Syntro Corporation (NASDAQ-NMS: SYNT), Hoechst-Roussel Agri-Vet Company and Hoechst Veterinar GmbH announced today that final agreements have been reached to collaborate on two major programs to develop families of innovative vaccines for cattle and horses, utilizing Syntro's viral vector technology. Funding required to carry out the multiyear product development programs will approximate $6 million and will be provided by the Hoechst companies.
 Under terms of the agreements, Syntro and its subsidiary SyntroVet Incorporated will spearhead the product development activities, manufacture the final vaccines for specified territories and receive royalties on sales. The Hoechst companies will receive, in return, exclusive worldwide marketing rights for products defined in the agreements. The cattle vaccine collaboration targets four important respiratory and reproductive diseases affecting beef and dairy animals. The equine product development effort is aimed at vaccines against three diseases affecting performance and breeding horses.
 "The new agreements expand the scope of our collaboration with the Hoechst organization in a major way," stated Dr. J. Donald Todd, Syntro's president and CEO. "We have been working with Hoechst for over a year to develop innovative, viral-vectored vaccines for poultry. The progress we have made has underscored the potential for this exciting new approach to disease prevention and has prompted our companies to expand the program into cattle and equine areas."
 Syntro's viral vector technology utilizes genetic engineering techniques to custom design and construct vaccines that provide improved efficacy, safety and diagnostic features useful for disease eradication programs. Viral vector vaccines consist of single viruses that have been genetically programmed to induce immunity against multiple diseases.
 Dieter Haas, managing director of Hoechst's animal health activities, stated, "We are expanding our commitment to the veterinary vaccine field because we expect this sector to benefit from the dramatic advances in biotechnology. Syntro's viral vector vaccines provide a good opportunity for us. The products are expected to be useful for the prevention of many diseases of veterinary importance."
 H. Newton Williams, vice president and general manager of the animal health business of Hoechst-Roussel Agri-Vet Company, was equally enthusiastic about the expanded relationship with Syntro. "The new collaborations are expected to yield vaccines that will dramatically reduce the incidence and impact of infectious respiratory and reproductive diseases of cattle and horses. These diseases are a very large problem in the United States and around the world. New vaccines are needed. We view our agreements with Syntro as a way to remain at the forefront of veterinary disease prevention and strengthen our worldwide animal health activities."
 Hoechst-Roussel Agri-Vet Company is a part of the Life Sciences Group of Hoechst Celanese Corporation of Somerville, N.J., a wholly owned subsidiary of Hoechst AG of Frankfurt, Germany. Hoechst-Roussel Agri-Vet Company is the Hoechst business unit with responsibility for animal health activities in North America. Hoechst Veterinar is a wholly owned subsidiary of Hoechst AG with responsibility for coordinating Hoechst AG animal health activities worldwide. Hoechst AG is the seventh largest supplier of animal health products in the world.
 Syntro Corporation is a Kansas City and San Diego based biotechnology company engaged in the development and commercialization of genetically engineered vaccines for the animal health market. SyntroVet Incorporated, a wholly-owned subsidiary of Syntro, manufactures and markets products resulting from Syntro's research and collaborative efforts.
 -0- 7/30/92 R P
 /CONTACT: Jack Falker of Swenson Falker Eilertsen, 612-371-0000 or Dr. J. Donald Todd of Syntro, 913-888-8876 or Andrea Stine of Hoechst- Roussel Agri-Vet Company, 908-231-3752/
 (SYNT) CO: Syntro Corporation; Hoechst-Roussel Agri-Vet Company ST: Missouri, New Jersey IN: MTC SU: JVN


KH -- MN003 -- 5326 07/30/92 17:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 30, 1992
Words:610
Previous Article:AMBAC INC. ANNOUNCES SECOND QUARTER EARNINGS OF $30.7 MILLION; EARNINGS INCREASE 10.4 PERCENT
Next Article:THE HANOVER INSURANCE COMPANY 1992 SECOND QUARTER EARNINGS
Topics:


Related Articles
SYNTRO REPORTS FOURTH QUARTER PROFIT AND IMPROVED OPERATING RESULTS FOR FISCAL 1991
SYNTRO AND HOECHST TO DEVELOP VACCINES
BAYER TO MARKET SYNTRO VACCINE IN EUROPE
HOECHST & SYNTRO EXPAND COLLABORATION TO DEVELOP VACCINES
SYNTRO VIRAL VECTOR VACCINE APPROVED FOR FINAL TESTING
SYNTRO REPORTS SECOND QUARTER RESULTS
MALLINCKRODT TO MAKE TENDER OFFER FOR SYNTRO CORPORATION STOCK
MALLINCKRODT TO MAKE TENDER OFFER FOR SYNTRO CORPORATION STOCK
Hoechst Roussel Vet Drops Suit Against Mallinckrodt Inc., J. P. Morgan
Hoechst Roussel Vet and Central Garden and Pet Company Sign Memorandum Of Understanding for Joint Development, Marketing and Distribution

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters